Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Galapagos Stock Quote

Galapagos (NASDAQ: GLPG)

Price as of November 29, 2023, 4:00 p.m. ET

You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Galapagos Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
GLPG -5.57% -63.30% -18.17% +371%
S&P +13.02% +65.84% +10.65% +263%

Galapagos Company Info

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

News & Analysis


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.